FDA Clears the XO Score Percutaneous Transluminal Angioplasty (PTA) Scoring Sheath platform

For Use in Iliac, Ilio-femoral, Popliteal, Infra-Popliteal, and Renal Arterial Plus Synthetic and/or Native Arteriovenous Hemodialysis Fistula

XO Score Percutaneous Transluminal Angioplasty: Transit Scientific notes: Angioplasty is performed with expandable polymer balloon catheters to dilate stenosed, or narrowed, vessels. Calcified, fibrous, and/or resilient stenosis may require special scoring or cutting angioplasty balloons with integrated wires or blades on the balloon. The added features focus and improve dilating force but result in large crossing profiles and limited deliverability while increasing cost and inventory.

XO Score transforms regular PTA balloons into scoring and cutting systems,” said Greg Method, President, Transit Scientific, Park City, Utah. “Clinicians insert an off-the-shelf PTA balloon into the XO Score tableside and then the system can be used over-the-wire to dilate calcified plaque and prep vessels.”

The XO Score is a patented, low-profile, flexible, metal-alloy exoskeleton with a balloon expandable scoring section. One XO Score sheath can be used with a number of 4-8mm diameter and 20-40mm long balloons to save the hospital, outpatient lab, ambulatory surgery center (ASC), or office-based lab (OBL) money on each scoring or cutting procedure.

XO Score is a new way to prep the vessel,” said Jihad Mustapha, MD Interventional Cardiologist, Advanced Cardiac & Vascular Center, Grand Rapids, MI. “The low-profile design is smooth for tracking to and from the treatment site. But, during balloon inflation, XO Score struts rotate 90° on edge to score and cut. Upon deflation, the XO Score rewraps back-to-flat for smooth withdraw.”

Competitive scoring/cutting balloons feature 1-5 fixed-depth scoring wires/blades that add bulk, profile, and stiffness. XO Score has up to 22 scoring/cutting struts that lay flat while tracking but rotate 90° during balloon inflation to score and cut 0.25mm (0.010″), 0.35mm (0.014″), or 0.50mm (0.020″) deep. Struts rotate 90° back during deflation.

“XO Score adds new technology and value to angioplasty,” continued Mr. Method. “Rotating struts allow clinicians to vary scoring depth without increasing device profile. Economically, XO Score offers a direct value proposition: (1) XO Score + (1) off-the-shelf PTA balloon will cost less than (1) specialty PTA scoring or cutting technology.”

This FDA clearance covers the 6.3Fr (French) XO Score in 65cm & 125cm working lengths with 0.25mm (0.010″), 0.35mm (0.014″), or 0.50mm (0.020″) scoring or cutting depths to enable precise dilation across a range of lesion types. Future 3Fr, 4Fr, and 5Fr over-the-wire and rapid-exchange XO Score versions are under development for smaller vessel and coronary use.

In May 2020, Transit Scientific received FDA clearance for the XO Cross 2Fr, 2.6Fr, and 3.8Fr low-profile, high-torque, and high-push non-tapered microcatheter platform. Transit Scientific is a private company with more than 26 combined issued and pending patents to commercialize medical devices including the FDA cleared XO Score® and XO Cross® platforms.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.